news L
umenis has announced that the company supported a successful mission to treat children with burn injuries in Armenia.
Lumenis Ltd, the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmology applications announced that the company supported a successful mission to treat children with burn injuries in Armenia. The mission, led by R. Rox Anderson, MD, Director of the Wellman Center for Photomedicine and Professor of Dermatology at Harvard Medical School, was designed to provide immediate access to treatment for patients in need, but also to help local medical leaders establish a sustainable burn injury care network in Armenia. The Lumenis UltraPulse®, the most powerful
CO2
laser system for scar revision procedures, with the unique SCAARFX mode, was used in the mission. It has also been used in similar humanitarian initiatives in Russia, China and Vietnam, and is considered the standard of care for treating soldiers injured in battle, for example in the VA hospitals in the USA.
Bayer HealthCare announced that the US Food and Drug Administration (FDA) has approved Finacea® (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea® Foam compared to its foam vehicle (without the drug azelaic acid) in the topical treatment of
| NEWS
A round-up of news stories in the aesthetic and anti-ageing medicine industry
LUMENIS SUPPORTS MISSION TO PROVIDE TREATMENTS FOR CHILDREN IN ARMENIA
DOCTORS PERFORMED LASER PROCEDURES TO TREAT CHILDREN WITH BURN INJURIES
to establish a medical laser center in Arabkir Pediatric Hospital where physicians can be trained to perform laser procedures for children with vascular anomalies and scars. ‘It is important to remember that scars do
‘Unfortunately, sometimes the most effective and innovative healthcare technologies don’t get to the patients who need them most,’ said Dr. Anderson. ‘We’re determined to change that. Children with burn injuries whether they live in the suburbs of New York City or a small village in Armenia — should have access to treatments like UltraPulse.’ This is Dr. Anderson’s second trip to Armenia.
In October 2013, a team that also included Dr. Lilit Garibyan of Massachusetts General Hospital and Dr. Ray Jalian of Ronald Reagan UCLA Medical Center treated more than 40 patients in Yerevan. The ultimate goal of the 2015 mission is
not just affect a patient’s appearance,’ said Dr. Hrachya Arshakyan, chief of the plastic surgery department. ‘For many patients with burn injuries, chronic pain and physical discomfort from their scars create a major quality of life burden. Range of motion can also be compromised due to severe scarring. These complex cases require advanced laser technologies like UltraPulse with SCAARFX that can penetrate deep into the skin, helping to aid healthy skin regeneration.’ ‘Lumenis is honored to be supporting this
important mission to help children in Armenia,’ said Tzipi Ozer-Armon, CEO of Lumenis. ‘The approach used by Dr. Anderson and the
Wellman Center creates enduring change by empowering local medical leaders. The benefits of these missions last for many years and continue to grow as more physicians are trained on the technology and more patients receive access to life-changing treatments.’
FDA APPROVE FINACEA® FOAM FOR TREATMENT OF ROSACEA
papulopustular rosacea. Papulopustular rosacea is a skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead. In two pivotal clinical trials,
treatment with Finacea® Foam resulted in a higher Investigator’s Global Assessment (IGA) success rate compared to vehicle control (32.1% vs. 23.4% in trial 1 and 43.4% vs. 32.5% in trial 2), as well as a
greater reduction in the mean nominal change of inflammatory lesion count from baseline to the end of the 12-week treatment period (-13.2 vs. -10.3 in trial 1 and -13.3 vs. -9.5 in trial 2). The most frequently observed adverse reactions in 0.5% of subjects treated with Finacea® Foam included local application site pain (6.2%), pruritus (2.5%), dryness (0.7%), and erythema (0.7%). ‘The FDA approval of Finacea®
Foam is the result of several years of research and development,’ said James Robins, VP & General Manager, Bayer HealthCare Pharmaceuticals Inc. ‘Not only does it add to our current product line, it also demonstrates Bayer’s continued commitment to addressing the needs of patients with mild to moderate rosacea.’ Finacea® Foam will be available by prescription only beginning in September 2015.
prime-journal.com | August/September 2015 9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64